Chengdu, China, October 25, 2021
Anticancer Bioscience Has Been Named as One of the ‘50 Most Admired Companies Of The Year 2021’ By The Silicon Review
Chengdu, China, October 25, 2021 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, has been named as one of the ‘50 Most Admired Companies of the Year 2021’ by The Silicon Review.
ACB is a growing precision therapeutics company headquartered in Chengdu, China, with global research and development teams in India, Australia, the United Kingdom, and the United States. ACB is applying synthetic lethal approaches to develop targeted cancer therapies that have the potential to be much safer and more effective than current therapies. ACB has access to world-leading cancer biology expertise and proprietary drug discovery platforms that enable the company to identify novel compounds that can target both genetic and epigenetic vulnerabilities of cancer cells. ACB has bespoke chemical compound libraries and has invested in developing one of the world’s largest natural product libraries, providing a rich screening resource for potential cancer therapeutics.
A profile of the history of the company and its foundation by Dun Yang PhD, President, and CEO of ACB is published online HERE.
Commenting in the article he said: “ACB’s expertise in synthetic lethal approaches to precision oncology, MYC biology, and cell division has allowed the company to build a broad pipeline that paves the way to develop novel cancer therapies.”
For further information, please contact:
At the company
+44 (0) 7968 726585
About Anticancer Bioscience
Anticancer Bioscience (ACB) is an international private company, commercializing discoveries emerging from China’s world-leading cancer research at the J. Michael Bishop Institute of Cancer Research. With pioneers in synthetic lethal approaches to precision oncology and experts in MYC biology and cell division, ACB was founded in 2016 in Chengdu, China. ACB is based on over 20 years of collaborative research between the founder Dr. Dun Yang and his Nobel laureate mentor Dr. J. Michael Bishop. It has raised CNY131M (around USD21M) and has around 50 employees in Chengdu, China, Hyderabad, India, Sydney, Australia, St Andrews, UK, and San Francisco, USA.